"Carcinoma, Squamous Cell/drug therapy*"[MeSH Major Topic] - Search Results

Year	Number of Results
1965	7
1966	10
1967	22
1968	27
1969	40
1970	21
1971	37
1972	37
1973	30
1974	32
1975	31
1976	38
1977	36
1978	54
1979	77
1980	59
1981	73
1982	88
1983	87
1984	121
1985	115
1986	125
1987	125
1988	103
1989	132
1990	127
1991	113
1992	139
1993	121
1994	129
1995	130
1996	161
1997	151
1998	151
1999	149
2000	156
2001	206
2002	171
2003	220
2004	235
2005	253
2006	287
2007	289
2008	272
2009	336
2010	370
2011	376
2012	367
2013	374
2014	398
2015	435
2016	440
2017	483
2018	438
2019	534
2020	649
2021	601
2022	661
2023	604
2024	246

1

Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics.

Yang Y, Li Y, Yu H, Ding Z, Chen L, Zeng X, He S, Liao Q, Zhao Y, Yuan Y. Yang Y, et al. Signal Transduct Target Ther. 2023 Aug 11;8(1):298. doi: 10.1038/s41392-023-01518-0. Signal Transduct Target Ther. 2023. PMID: 37563120 Free PMC article. No abstract available.

2

Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance.

Fan J, Lu F, Qin T, Peng W, Zhuang X, Li Y, Hou X, Fang Z, Yang Y, Guo E, Yang B, Li X, Fu Y, Kang X, Wu Z, Han L, Mills GB, Ma X, Li K, Wu P, Ma D, Chen G, Sun C. Fan J, et al. Nat Genet. 2023 Dec;55(12):2175-2188. doi: 10.1038/s41588-023-01570-0. Epub 2023 Nov 20. Nat Genet. 2023. PMID: 37985817

3

Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial.

Liu Q, Chen J, Lin Y, Ye J, Shen W, Luo H, Li B, Huang W, Wei S, Song J, Wang Y, Yang H, Lai S, Zhu H, Ai D, Chen Y, Deng J, Hao S, Zhao K. Liu Q, et al. Lancet Gastroenterol Hepatol. 2024 Jan;9(1):45-55. doi: 10.1016/S2468-1253(23)00316-3. Epub 2023 Nov 18. Lancet Gastroenterol Hepatol. 2024. PMID: 37980921 Clinical Trial.

4

Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma.

Lin S, Sun Y, Cao C, Zhu Z, Xu Y, Liu B, Hu B, Peng T, Zhi W, Xu M, Ding W, Ren F, Ma D, Li G, Wu P. Lin S, et al. EBioMedicine. 2023 Nov;97:104846. doi: 10.1016/j.ebiom.2023.104846. Epub 2023 Oct 24. EBioMedicine. 2023. PMID: 37879219 Free PMC article.

5

Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.

Yin J, Yuan J, Li Y, Fang Y, Wang R, Jiao H, Tang H, Zhang S, Lin S, Su F, Gu J, Jiang T, Lin D, Huang Z, Du C, Wu K, Tan L, Zhou Q. Yin J, et al. Nat Med. 2023 Aug;29(8):2068-2078. doi: 10.1038/s41591-023-02469-3. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488287 Free PMC article. Clinical Trial.

6

Pharmacological targeting of netrin-1 inhibits EMT in cancer.

Lengrand J, Pastushenko I, Vanuytven S, Song Y, Venet D, Sarate RM, Bellina M, Moers V, Boinet A, Sifrim A, Rama N, Ducarouge B, Van Herck J, Dubois C, Scozzaro S, Lemaire S, Gieskes S, Bonni S, Collin A, Braissand N, Allard J, Zindy E, Decaestecker C, Sotiriou C, Salmon I, Mehlen P, Voet T, Bernet A, Blanpain C. Lengrand J, et al. Nature. 2023 Aug;620(7973):402-408. doi: 10.1038/s41586-023-06372-2. Epub 2023 Aug 2. Nature. 2023. PMID: 37532929 Free PMC article.

7

Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway.

Zhang JW, Zhang D, Yin HS, Zhang H, Hong KQ, Yuan JP, Yu BP. Zhang JW, et al. Gut Microbes. 2023 Jan-Dec;15(1):2197836. doi: 10.1080/19490976.2023.2197836. Gut Microbes. 2023. PMID: 37017266 Free PMC article.

8

Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.

Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo SY, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Gross ND, et al. Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875144 Clinical Trial.

9

Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia.

Fang K, Sun M, Leng Z, Chu Y, Zhao Z, Li Z, Zhang Y, Xu A, Zhang Z, Zhang L, Chen T, Xu M. Fang K, et al. J Exp Clin Cancer Res. 2023 Mar 28;42(1):73. doi: 10.1186/s13046-023-02623-2. J Exp Clin Cancer Res. 2023. PMID: 36978187 Free PMC article.

10

Combination therapy with WEE1 inhibition and trifluridine/tipiracil against esophageal squamous cell carcinoma.

Nguyen Vu TH, Kikuchi O, Ohashi S, Saito T, Ida T, Nakai Y, Cao Y, Yamamoto Y, Kondo Y, Mitani Y, Kataoka S, Kondo T, Katada C, Yamada A, Matsubara J, Muto M. Nguyen Vu TH, et al. Cancer Sci. 2023 Dec;114(12):4664-4676. doi: 10.1111/cas.15966. Epub 2023 Sep 19. Cancer Sci. 2023. PMID: 37724648 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

11,131 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

11,131 results

Results by year